Clinical Trials Directory

Trials / Conditions / Leukemia, Lymphocytic

Leukemia, Lymphocytic

14 registered clinical trials studyying Leukemia, Lymphocytic — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingAnti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Mali
NCT06462248
Chi Kong LiPhase 2
RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/S
NCT05254743
Loxo Oncology, Inc.Phase 3
CompletedPalbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (
NCT03792256
Children's Oncology GroupPhase 1
CompletedBiomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias
NCT01144793
Stanford University—
CompletedA Study of Enzastaurin in Patients With Leukemia
NCT00452257
Eli Lilly and CompanyPhase 1
CompletedTreatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
NCT00327678
Assistance Publique - Hôpitaux de ParisPhase 3
CompletedMonoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic
NCT00313079
Steven E. CoutrePhase 1
UnknownIdentifying Characteristics of Bone Marrow Failure Syndromes
NCT00315419
Office of Rare Diseases (ORD)—
TerminatedT-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
NCT00306332
Radboud University Medical CenterPhase 3
CompletedBusulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00361140
H. Lee Moffitt Cancer Center and Research InstitutePhase 4
CompletedStudy of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
NCT00035022
BioCryst PharmaceuticalsPhase 1 / Phase 2
CompletedStudy of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
NCT00034684
Merck Sharp & Dohme LLCPhase 1 / Phase 2
CompletedSelective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
NCT00025662
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
CompletedEpoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
NCT00270049
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2